Sinocelltech Gains NMPA Clearance for SCTB39-1 Clinical Study in Advanced Solid Tumors
CompanyDrug

Sinocelltech Gains NMPA Clearance for SCTB39-1 Clinical Study in Advanced Solid Tumors

Santen's Ryjunea Gets EU Approval to Slow Myopia Progression in Children
CompanyDrug

Santen’s Ryjunea Gets EU Approval to Slow Myopia Progression in Children

Takeda's Shan Guohong Departs to Join BeOne Medicines as Next Career Move
Company

Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move

Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub
CompanyDeals

Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub”

Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges
Company

Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges

Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics
CompanyDeals

Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics

Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers
CompanyDeals

Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers

Sino Biopharmaceutical's TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment
CompanyDrug

Sino Biopharmaceutical’s TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment

3D Medicines Partners with MGI Tech for Precision Medicine Solutions in Oncology and Infectious Diseases
CompanyDeals

3D Medicines Partners with MGI Tech for Precision Medicine Solutions in Oncology and Infectious Diseases

Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia
CompanyDeals

Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia

bioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline
CompanyDeals

BioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline

Suzhou GenAssist's GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy
CompanyDrug

Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy